Merck's small molecule cancer drug, acquired for over $1.3 billion, launches Phase 3 clinical trials in China
芊芊551
发表于 2024-7-24 18:35:33
199
0
0
According to the latest announcement on the Chinese Drug Clinical Trial Registration and Information Disclosure Platform, Merck's Class 1 oral drug MK-3543 (bomedemstat) for the treatment of primary thrombocytopenia has started Phase 3 clinical trials. Bomedemstat is an oral lysine specific demethylase 1 (LSD1) inhibitor, which Merck acquired from Imago BioSciences for approximately $1.35 billion in 2022.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Has the 'fixed price' policy been effective? General Motors' sales in China increased by 14.3% month on month in the third quarter, and SAIC GM's orders for certain models were overstocked
- Hyatt Hotels and China Resources Land establish a joint venture for light asset expansion, continuing to expand into the Chinese market
- The Boston Science Harbor Base has been completed and opened, achieving "independent production" in China
- When will Apple AI be launched in China? Cook responds!
- Dialogue with Meng Pu, Chairman of Qualcomm China: Qualcomm has long-term accumulation in China and will adhere to the path of self-developed chips
- This US funded enterprise has clarified its confidence and direction for development in China through the CIIE
- Pfizer's innovative targeted therapy drug Taizena has been approved in China
- AbbVie Dual Anti Cancer New Drug Declares for Market in China
- Abbott announces the launch of its new women's health drug Fenyouning in China
- A sharp drop of 87%! Maserati will only sell over 30 units in China in September! Has the 'Sports Car Queen' fallen from grace?
-
11월 14일, 세계예선 아시아지역 제3단계 C조 제5라운드, 중국남자축구는 바레인남자축구와 원정경기를 가졌다.축구 국가대표팀은 바레인을 1-0으로 꺾고 예선 2연승을 거두었다. 특히 이번 경기 국내 유일한 중계 ...- 我是来围观的逊
- 16 분전
- Up
- Down
- Reply
- Favorite
-
"영비릉: 2024회계연도 영업수입 동기대비 8% 감소"영비릉은 2024회계연도 재무제보를 발표했다.2024 회계연도 매출은 149억5500만 유로로 전년 동기 대비 8% 감소했습니다.이익은 31억 500만 유로입니다.이익률은 ...- 勇敢的树袋熊1
- 3 일전
- Up
- Down
- Reply
- Favorite
-
계면신문기자 장우발 4분기의 영업수입이 하락한후 텐센트음악은 다시 성장으로 돌아왔다. 11월 12일, 텐센트음악은 최신 재보를 발표했다.2024년 9월 30일까지 이 회사의 3분기 총수입은 70억 2천만 위안으로 전년 ...
- 勇敢的树袋熊1
- 그저께 15:27
- Up
- Down
- Reply
- Favorite
-
본사소식 (기자 원전새): 11월 14일, 다다그룹 (나스닥코드: DADA) 은 2024년 3분기 실적보고를 발표했다. 수치가 보여준데 따르면 고품질발전전략에 지속적으로 전념하고 사용자체험을 끊임없이 최적화하며 공급을 ...- 家养宠物繁殖
- 어제 15:21
- Up
- Down
- Reply
- Favorite
